AMS

Business Context and Reporting Period

Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1999

ASHS operates primarily through its 81% interest in GK Financing, LLC (GKF), providing Gamma Knife stereotactic radiosurgery services to eight medical centers in seven U.S. states. In November 1998, the Company sold its diagnostic imaging business, which previously accounted for the majority of its revenue. Consequently, Gamma Knife services represented 99.9% of total revenues in 1999. The Company is developing a new business plan for "The Operating Room for the 21st Century" (OR21) and exploring Internet-related opportunities, though neither is expected to generate significant revenue in the near term.

Key Financial Metrics (Year Ended Dec 31, 1999)

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 79.6% to $7.156 million, primarily due to the November 1998 sale of the diagnostic imaging division. However, Gamma Knife revenues increased 72.1% to $7.151 million, driven by the commencement of four new contracts and full-year inclusion of additional units.
• Profitability Shift: Net income dropped 86.5% to $2.707 million. The 1998 figure was inflated by a one-time $20.478 million gain on the sale of the imaging division. Excluding this gain, 1998 net income was $1.073 million, indicating a significant operational improvement in 1999.
• Cost Reduction: Costs of operations fell 91.6% to $2.165 million, and selling/administrative expenses dropped 64.8% to $1.803 million, reflecting the divestiture of the imaging business and reduced staff.
• Debt Increase: Total debt increased significantly from $10.7 million to $22.4 million. This increase is attributable to financing new Gamma Knife units, as the Company relieved itself of approximately $27.1 million in debt associated with the sold imaging division.
• Liquidity: Cash and cash equivalents increased to $12.9 million, aided by the release of restricted cash previously held for potential claims related to the imaging sale.

Outlook, Risks, and Management Commentary

• Expansion: The Company has signed agreements for four additional Gamma Knife sites under development or construction, with two more pending state regulatory approval. One site is projected to be operational in Q2 2000.
• Reimbursement Risk: A significant risk involves potential decreases in Medicare and third-party reimbursement rates. The proposed Ambulatory Product Classifications (APC) system could categorize radiosurgery under conventional radiation therapy, potentially reducing reimbursement for outpatient procedures.
• Competition: The Company faces competition from other Gamma Knife providers, direct sales by the manufacturer (Elekta), and alternative technologies like modified linear accelerators. The Company does not have an exclusive relationship with Elekta.
• Technology Obsolescence: Elekta is introducing an upgraded Gamma Knife unit costing approximately $3.4 million. Seven of the Company's existing units are upgradeable at an estimated cost of up to $900,000 each.
• Contract Renegotiation: The contract with Hospital Barra D'Or in Brazil is being renegotiated due to economic changes; failure to renegotiate could lead to termination.

Investor Verification Checklist

• Customer Concentration: Verify the stability of the top four customers (USC, Hoag, STMH, Yale), who collectively accounted for over 40% of 1999 revenues.
• Reimbursement Policy Changes: Monitor the implementation of the APC system and its specific impact on the two revenue-sharing contracts where income is directly tied to reimbursement rates.
• Debt Service Coverage: Assess the ability to service the increased debt load ($22.4 million) given the capital-intensive nature of acquiring new units and the lack of minimum volume guarantees in customer contracts.
• Upgrade Costs: Confirm the timeline and funding requirements for upgrading existing units to the new Elekta model to maintain competitiveness.
• Regulatory Approvals: Track the status of the two contracts pending state regulatory approval and the Certificate of Need (CON) requirements for new sites.